Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?

Dividend AI-generated analysis

📉 Gilead reported a trailing EPS of -$3.13 due to approximately $12 billion in acquired in-process R&D charges from deals with Arcellx, Tubulis, Ouro Medicines, and PepStar.

💰 Free cash flow of $4.798 billion in the third quarter covers the dividend about 4.6 times over, indicating a safe payout despite negative accounting earnings.

📈 Third-quarter revenue reached $8.30 billion with non-GAAP EPS of $2.55 beating the $2.21 consensus estimate.

💊 HIV sales rose 18% in the quarter, fueling core growth and contributing to overall financial stability.

🚀 Yeztugo quarterly sales climbed from $166 million to $305 million, with management expecting about $1 billion in full-year sales.

💵 Gilead raised its quarterly dividend to $0.82 and declared an additional $0.82 payout for Q4 2026, payable December 30.

📊 Adjusted non-GAAP full-year EPS is forecast between $8.75 and $9.10, implying a payout ratio of roughly 36% to 37%.

📈 The stock price increased 39.65% year to date, trading at $168.38 as investors focus on cash flow rather than headline EPS.

⚠️ Starting Jan 1, 2028, Biktarvy faces a Medicare Maximum Fair Price with a preliminary net revenue hit of about $1.5 billion.

🔮 Management projects total HIV revenue, product sales, and EPS to grow in 2028 compared with 2027.

Bullish Signals
  • Free cash flow of $4.798 billion covers the dividend about 4.6 times over, providing a strong safety margin for the payout.
  • Third-quarter revenue reached $8.30 billion with non-GAAP EPS of $2.55 beating the $2.21 consensus estimate.
  • HIV sales rose 18% in the quarter, demonstrating strong core business growth and market demand.
  • Yeztugo quarterly sales climbed to $305 million, up from $166 million a year prior, with full-year expectations near $1 billion.
  • The company raised its quarterly dividend to $0.82 and declared an additional $0.82 payout for Q4 2026.
  • Adjusted non-GAAP full-year EPS is projected between $8.75 and $9.10, resulting in a conservative payout ratio of roughly 36% to 37%.
  • The stock price surged 39.65% year to date, trading at $168.38 as investors recognize the value of its cash generation.
Risk Factors
  • Trailing EPS is -$3.13 due to approximately $12 billion in acquired in-process R&D charges recorded in the June quarter.
  • Starting Jan 1, 2028, Biktarvy faces a Medicare Maximum Fair Price with a preliminary net revenue hit of about $1.5 billion.
  • Cash and equivalents fell 12.18% to $6.437 billion following recent acquisitions.
Full Analysis
Gilead Sciences (GILD) reported a trailing twelve-month loss of $3.13 per share, driven primarily by approximately $12 billion in acquired in-process R&D charges recorded in the June quarter. Despite this accounting-driven negative earnings figure, the company maintains a robust financial position with free cash flow covering its dividend payments roughly 4.6 times over in the third quarter. The core business demonstrated resilience with third-quarter revenue reaching $8.30 billion and non-GAAP EPS of $2.55 beating analyst consensus. HIV sales grew by 18%, while Yeztugo, a twice-yearly HIV prevention shot, saw quarterly sales climb to $305 million. Management expects total HIV revenue, product sales, and EPS to grow in 2028 compared with 2027. Gilead raised its quarterly dividend to $0.82 and declared another $0.82 payout for the fourth quarter, payable December 30, 2026. Adjusted non-GAAP full-year EPS is projected between $8.75 and $9.10, resulting in a payout ratio of roughly 36% to 37%. The stock trades at $168.38, up 39.65% year to date, reflecting investor confidence in the dividend's safety despite the headline loss.